The UK's Izana Bioscience is the latest company to evaluate an immunomodulator as a treatment for coronavirus, and has initiated trials in Italy of its late-stage granulocyte-macrophage colony stimulating factor (GM-CSF) targeting antibody namilumab in patients with the infection.
The Oxford-based private biotech has just received the go-ahead from Italian regulators to start a two-center compassionate use study (in...